- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
CMS Issues Draft Coverage Decision For Prostate Cancer Test by GenomeDX
The Decipher test is intended for use in men who have undergone radical prostatectomy and are at a high risk of disease recurrence.
GenomeDx Biosciences today announced that a draft local coverage determination (LCD) for its Decipher® Prostate Cancer Classifier has been published by the Centers for Medicare and Medicaid Services (CMS) describing a coverage and payment policy for use of the Decipher test in men who have undergone radical prostatectomy. An LCD is a decision by Medicare contractors to cover an item or service. Decipher is the only genomic test for prostate cancer to receive a draft LCD for use in the post-surgery setting.
“The draft LCD is a major step toward providing access to Decipher for the thousands of prostate cancer patients weighing treatment options after radical prostatectomy,” said Doug Dolginow, M.D., CEO of GenomeDx. “We appreciate the opportunity to have worked collaboratively with the MolDX Program by Palmetto GBA®, and will continue to do so through the final steps in obtaining coverage.”
Under Medicare policies, a 45-day comment period will commence on November 10, 2014, for the draft LCD. After comments are received and revisions, if any, are made to the draft LCD, the final LCD will be posted within 45 calendar days.
Press release by GenomeDX: http://bit.ly/1sXrwOj
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
